From the Journals

Many Patients With Cancer Visit EDs Before Diagnosis


 

FROM CMAJ

‘Unpacking the Data’

The current findings also are consistent with those of an International Cancer Benchmarking Partnership study that was published in 2022 in The Lancet Oncology, said Erika Nicholson, MHS, vice president of cancer systems and innovation at the Canadian Partnership Against Cancer. The latter study analyzed cancer registration and linked hospital admissions data from 14 jurisdictions in Australia, Canada, Denmark, New Zealand, Norway, and the United Kingdom.

“We see similar trends in terms of people visiting EDs and being diagnosed through EDs internationally,” Nicholson said. “We’re working with partners to put in place different strategies to address the challenges” that this phenomenon presents in terms of improving screening and follow-up care.

“Cancer is not one disease, but many diseases,” she said. “They present differently. We’re focused on really unpacking the data and understanding them.”

All this research highlights the need for more services and personnel to address cancer, including people who are trained to help patients cope after getting concerning news through emergency care, she said.

“That means having a system that fully supports you and helps you navigate through that diagnostic process,” Nicholson said. Addressing the added challenges for patients who don’t have secure housing is a special need, she added.

This study was supported by the Canadian Institutes of Health Research (CIHR). Grewal reported receiving grants from CIHR and the Canadian Association of Emergency Physicians. Nicholson reported no relevant financial relationships.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

Cannabis in Cancer: What Oncologists and Patients Should Know
MDedge Hematology and Oncology
Should First-Line Dual Checkpoint Blockade Be Used for NSCLC With Specific Mutations?
MDedge Hematology and Oncology
For Radiation ‘Downwinders,’ Cancer Compensation Is On Hold
MDedge Hematology and Oncology
Cancer’s Other Toll: Long-Term Financial Fallout for Survivors
MDedge Hematology and Oncology
Are Three Cycles of Chemotherapy as Effective as Six for Retinoblastoma?
MDedge Hematology and Oncology
Can Better Diet Improve Survival in Black Women With Ovarian Cancer?
MDedge Hematology and Oncology
ATA: Updates on Risk, Diagnosis, and Treatment of Thyroid Cancer
MDedge Hematology and Oncology
Outpatient CAR T: Safe, Effective, Accessible
MDedge Hematology and Oncology
Prostate Cancer Treatment Associated With More Complications
MDedge Hematology and Oncology
Plasma Omega-6 and Omega-3 Fatty Acids Inversely Associated With Cancer
MDedge Hematology and Oncology